INMB Inmune Bio, Inc.
Price Chart
Executive Summary
INmune Bio reported statistically significant treatment effects on a white matter MRI biomarker (chi-separation) from the Phase 2 MINDFuL trial of XPro1595 in early Alzheimer's disease. The full mITT population (n=200) showed p=0.0028 with a medium effect size (d=0.46), strengthening to d=0.59 in biomarker-enriched patients (n=100). These results validate target engagement and support the upcoming Phase 2b/3 registrational program, which has FDA Fast Track designation and End-of-Phase 2 alignment.
Actionable Insight
This is a material pipeline de-risking event for INMB. The statistically significant biomarker results across the full study population, strengthening in the target-enriched subgroup, directly validate the Phase 2b/3 registrational design. Watch for AAIC 2026 presentation (July 12-15) for complete dataset including dose-response and longitudinal trajectory. The favorable safety profile (no ARIA-E/H) is a key differentiator vs amyloid-clearing competitors. Monitor for any capital raise announcements to fund the registrational program.
Key Facts
- Statistically significant treatment effect on myelin in full mITT population (p=0.0028; Cohen's d=0.46; n=200)
- Effect strengthened in biomarker-enriched patients (p=0.0098; d=0.59; n=100), validating precision-medicine approach
- FDA Fast Track designation granted May 14, 2026 for XPro in early Alzheimer's disease
- End-of-Phase 2 alignment secured with FDA on Phase 2b/3 seamless adaptive registrational design
- No ARIA-E or ARIA-H observed in Phase 2 MINDFuL trial — favorable safety differentiation vs amyloid-clearing agents
- Complete chi-separation dataset to be presented at AAIC 2026 (July 12-15, 2026 in London)
Financial Impact
No financial figures reported. Positive clinical catalyst for a $37M market cap biotech with no approved products — potential for significant stock re-rating on registrational program de-risking.
Risk Factors
- Phase 2b/3 registrational trial may fail to replicate these biomarker results on cognitive endpoints
- Company will require substantial additional funding to complete the registrational program — dilutive financing risk
- XPro1595 is not yet approved by FDA or any regulatory body; regulatory approval is uncertain
- Competition from approved amyloid-clearing therapies and other neuroinflammation-targeting programs
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-064144 |
| Document: ea0293325-8k_inmune.htm | 0001213900-26-064144 |
| Document: 0001213900-26-064144-index-headers.html | 0001213900-26-064144 |
| Document: 0001213900-26-064144-index.html | 0001213900-26-064144 |
| Document: 0001213900-26-064144.txt | 0001213900-26-064144 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 2, 2026
2d ago
|
8-K
| $1.32 $1.35 | ▲ +2.27% | ▲ +1.87% | $1.26 (−4.17%) |
|
May 7, 2026
28d ago
|
Press Release
| $1.43 $1.35 | ▼ −5.59% | ▼ −5.83% | $1.26 (−11.54%) |
|
May 5, 2026
4w ago
|
8-K
| $1.52 $1.43 | ▼ −5.92% | ▼ −5.59% | $1.26 (−16.78%) |
|
Apr 30, 2026
5w ago
|
Press Release
| $1.43 $1.51 | ▼ −5.59% | ▼ −5.37% | $1.26 (+11.54%) |
|
Mar 30, 2026
9w ago
|
Press Release
| $1.13 $1.23 | ▲ +8.85% | ▲ +8.10% | $1.26 (+11.95%) |
|
Mar 19, 2026
11w ago
|
Press Release
| $1.22 $1.17 | ▼ −4.10% | ▼ −2.36% | $1.26 (+3.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access